Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of being satiated, with the biopharma paying $25 million upfront to Arrowhead ...

The Angels reassigned Madrigal to minor-league camp Saturday. Madrigal inked a minor-league deal with an invitation to spring training back in January, but he appears set to open the season in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Warren Madrigal had a historic MLS debut for Nashville SC, becoming the first player in club history with two or more goal contributions in his first league game. The 21-year-old forward from Costa ...

Madrigal Pharmaceuticals (MASH) has reached an exclusive licensing agreement with China-based Suzhou Ribo Life Science to jointly develop treatments targeting a liver disease called metabolic ...

Feb 11 (Reuters) - Madrigal Pharmaceuticals (MDGL.O), opens new tab said on Wednesday it has entered into a global licensing deal with China-based Suzhou Ribo Life Science (6938.HK), opens new tab for ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. Just weeks after betting $50 million on a DGAT2i ...

Madrigal Pharma was the first drugmaker to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, and has now signed a major alliance with China's Ribo Life Science ...

The Angels are in agreement with Nick Madrigal on a minor league contract, reports Robert Murray of FanSided. The Wasserman client gets a non-roster invite to big league camp. Madrigal spent the ...

When I last covered Madrigal Pharmaceuticals (MDGL) in February last year, I was reviewing the company's Q4 and full-year 2024 earnings. Rezdiffra, Madrigal's only commercial asset, the first drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals is ...

Madrigal Pharmaceuticals' Rezdiffra generated sales of $287 million in the third quarter for a 35% sequential jump from Q2. In just its fifth full quarter on the market, the world’s first treatment ...